{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:27:14Z","timestamp":1784024834770,"version":"3.55.0"},"reference-count":24,"publisher":"BMJ","issue":"e2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2017,6,12]]},"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1136\/ejhpharm-2017-001221","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T06:17:05Z","timestamp":1507616225000},"page":"e115-e119","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Physical and chemical stability of ceftaroline in an elastomeric infusion device"],"prefix":"10.1136","volume":"25","author":[{"given":"Farah","family":"Al Madfai","sequence":"first","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Tabish R","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long Chiau","family":"Ming","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia"},{"name":"School of Pharmacy, KPJ Healthcare University College, Nilai, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Wanandy","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Royal Hobart Hospital, Hobart, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul P","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"2025090502151410000_25.e2.e115.1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s15010-015-0749-y","article-title":"Novel antibiotics: are we still in the pre-post-antibiotic era?","volume":"43","author":"Draenert","year":"2015","journal-title":"Infection"},{"key":"2025090502151410000_25.e2.e115.2","first-page":"12","article-title":"Antibiotic resistance threats in the United States","volume":"31","author":"US department of health and human service","year":"2014","journal-title":"Med Benefits"},{"key":"2025090502151410000_25.e2.e115.3","unstructured":"O`Neill J . Review on antimicrobial resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. UK: UK government, 2014."},{"key":"2025090502151410000_25.e2.e115.4","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013 http:\/\/www.cdc.gov\/drugresistance\/threat-report (accessed 22 Oct 2016)."},{"key":"2025090502151410000_25.e2.e115.5","unstructured":"European Centre for Disease Prevention and Control Antimicrobial Resistance. Antimicrobial resistance surveillance in Europe: annual report of the European antimicrobial resistance surveillance network (EARS-Net). 2012 https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/antimicrobial-resistance-surveillance-europe-2012.pdf (accessed 22 Oct 2016)."},{"key":"2025090502151410000_25.e2.e115.6","unstructured":"Crossley KB , Archer G , Jefferson K , et al . The staphylococci in human disease. New Jersey, USA: Wiley Online Library, 1997."},{"key":"2025090502151410000_25.e2.e115.7","doi-asserted-by":"publisher","DOI":"10.1086\/519470"},{"key":"2025090502151410000_25.e2.e115.8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01308-10"},{"key":"2025090502151410000_25.e2.e115.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01516-09"},{"key":"2025090502151410000_25.e2.e115.10","unstructured":"AstraZeneca A . Zinforo 600 mg powder for concentrate for solution for infusion: EU summary of product characteristics. 2012."},{"key":"2025090502151410000_25.e2.e115.11","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-012-0449-9"},{"key":"2025090502151410000_25.e2.e115.12","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks006"},{"key":"2025090502151410000_25.e2.e115.13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/phar.1681","article-title":"Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis","volume":"36","author":"Autry","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2025090502151410000_25.e2.e115.14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"2025090502151410000_25.e2.e115.15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.12968\/bjca.2006.1.5.21121","article-title":"Is hospital the best place for patient with infective endocarditis: a review of the literature","volume":"5","author":"Siefers","year":"2006","journal-title":"B J Cardiac Nursing"},{"key":"2025090502151410000_25.e2.e115.16","doi-asserted-by":"publisher","DOI":"10.1086\/653520"},{"key":"2025090502151410000_25.e2.e115.17","unstructured":"Davey PWM , Irving W , Guy Thwaites G , et al . OPAT: outpatient parenteral antimicrobial therapy. London: Oxford University Press, 2013."},{"key":"2025090502151410000_25.e2.e115.18","unstructured":"Ashley S , Hajkowicz K , Halford M , et al . Outpatient parenteral antibiotic therapy: an economic, clinical, and humanistic analysis at a quaternary hospital. Queensland government. http:\/\/mm2015shpa.com\/wp-content\/uploads\/2015\/11\/052-Ashley-Sahra-Outpatient-Parenteral-Antibiotic-Therapy-OPAT-an-economic-clinical-and-humanistic-analysis-at-a-quaternary-hospital.pdf (accessed 22 Oct 2016)."},{"key":"2025090502151410000_25.e2.e115.19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg061"},{"key":"2025090502151410000_25.e2.e115.20","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C153"},{"key":"2025090502151410000_25.e2.e115.21","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh146"},{"key":"2025090502151410000_25.e2.e115.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(03)00065-5"},{"key":"2025090502151410000_25.e2.e115.23","first-page":"228-31","article-title":"Types and causes of medication errors from nurse\u2019s viewpoint","volume":"18","author":"Cheragi","year":"2013","journal-title":"Iran J Nurs Midwifery Res"},{"key":"2025090502151410000_25.e2.e115.24","first-page":"432","article-title":"In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers","volume":"19","author":"Bhattacharya","year":"2015","journal-title":"Int J Pharm Compd"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2017-001221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T09:15:56Z","timestamp":1757063756000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2017-001221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":24,"journal-issue":{"issue":"e2","published-online":{"date-parts":[[2018,9,16]]},"published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1136\/ejhpharm-2017-001221"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2017-001221","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]}}}